share_log

Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $31 Price Target

Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $31 Price Target

巴靈頓研究將Anika Therapeutics上調至跑贏大盤,宣佈目標股價爲31美元
Benzinga Real-time News ·  2022/11/09 22:31

Barrington Research analyst Michael Petusky upgrades Anika Therapeutics (NASDAQ:ANIK) from Market Perform to Outperform and announces $31 price target.

巴靈頓研究分析師邁克爾·佩圖斯基將Anika Therapeutics(納斯達克股票代碼:ANIK)從市場表現上調至跑贏大盤,並宣佈了31美元的目標股價。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論